Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kangfuxin enteric capsule + mesalazine vs placebo + mesalazine in mild to moderate active ulcerative colitis
ChiCTR2500109104Phase 2Recruiting
- Sponsor
- Shanghai Tenth People's Hospital
- Start
- Sep 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Treatment arm: mesalazine + Kangfuxin enteric capsule with Placebo arm: mesalazine + placebo capsule (2 arms). Primary endpoints: Clinical remission rate, Endoscopic remission rate and 4 more. Started Sep 2025; status: recruiting.
02
Drugs
kangfuxin enteric capsule
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ChiCTR2500109104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109104.